US Stock MarketDetailed Quotes

Seres Therapeutics (MCRB)

Watchlist

7.700
-0.020-0.26%

Close May 8 16:00 ET

7.700
0.0000.00%

Post 20:01 ET

74.57MMarket Cap-1.48P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Seres Therapeutics (MCRB) Income Statement

Quarterly+Annual

YOY

Hide blank lines

(Q1)Mar 31, 2026

(FY)Dec 31, 2025

(Q4)Dec 31, 2025

(Q3)Sep 30, 2025

(Q2)Jun 30, 2025

(Q1)Mar 31, 2025

(FY)Dec 31, 2024

(Q4)Dec 31, 2024

(Q3)Sep 30, 2024

(Q2)Jun 30, 2024

Total revenue

358K

789K

Operating revenue

--358K

--789K

--0

Cost of revenue

85.28%6.54M

-83.24%592K

736K

1.69M

3.53M

Gross profit

110.15%358K

-62.94%-5.76M

105.58%197K

-736K

-1.69M

-3.53M

Operating expense

-10.31%21.27M

-25.10%88.22M

-22.64%19.57M

-25.47%21.74M

-19.67%23.19M

-31.15%23.71M

-39.63%117.78M

-31.66%25.3M

-34.58%29.17M

-62.48%28.87M

Selling and administrative expenses

-32.12%8.07M

-26.37%39.16M

-39.50%7.54M

-25.44%9.48M

-21.52%10.25M

-20.45%11.89M

-31.38%53.18M

-10.86%12.46M

-34.59%12.71M

-53.42%13.07M

-General and administrative expense

-32.12%8.07M

-26.37%39.16M

-39.50%7.54M

-25.44%9.48M

-21.52%10.25M

-20.45%11.89M

-31.38%53.18M

-10.86%12.46M

-34.59%12.71M

-53.42%13.07M

Research and development costs

11.62%13.2M

-24.06%49.06M

-9.01%11.68M

-23.35%12.62M

-18.14%12.94M

-39.36%11.82M

-45.07%64.6M

-44.27%12.84M

-34.56%16.46M

-66.22%15.81M

Other operating expenses

----

---351K

----

-222.93%-2.59M

Operating profit

23.24%-20.91M

22.54%-93.97M

32.80%-19.38M

22.94%-22.48M

13.82%-24.88M

20.91%-27.24M

37.82%-121.32M

22.12%-28.84M

34.58%-29.17M

-158.30%-28.87M

Net non-operating interest income expense

-47.41%325K

-43.86%2.23M

1.83%445K

-5.21%618K

-55.61%546K

-40.00%618K

-17.92%3.97M

-77.83%437K

-74.65%652K

184.19%1.23M

Non-operating interest income

-47.41%325K

-43.86%2.23M

1.83%445K

-5.21%618K

-55.61%546K

-62.50%618K

-45.66%3.97M

-77.83%437K

-74.65%652K

-28.74%1.23M

Non-operating interest expense

----

--0

----

--0

Other net income (expense)

-98.87%669K

1,256.83%97.44M

-71.81%3.6M

233.51%30.06M

210.03%4.48M

11,642.57%59.3M

-6,385.82%-8.42M

3,697.92%12.76M

-2,353.95%-22.52M

195.63%1.45M

Special income (charges)

--0

1,319.51%80.69M

-80.70%1.1M

--27.22M

--185K

--52.18M

--5.68M

--0

-Gain on sale of business

--0

1,319.51%80.69M

-80.70%1.1M

--27.22M

--185K

--52.18M

--5.68M

--0

Other non- operating income (expenses)

-90.60%669K

218.77%16.76M

-64.67%2.5M

112.62%2.84M

197.23%4.3M

1,309.70%7.12M

-10,627.61%-14.11M

2,006.25%7.08M

-2,353.95%-22.52M

195.63%1.45M

Income before tax

-160.93%-19.91M

104.53%5.7M

1.93%-15.34M

116.08%8.2M

24.21%-19.86M

199.33%32.68M

33.85%-125.77M

54.96%-15.64M

-24.43%-51.04M

-156.27%-26.2M

Income tax

Net income

-160.93%-19.91M

4,088.24%5.7M

1.93%-15.34M

-90.76%8.2M

39.60%-19.86M

181.43%32.68M

100.12%136K

62.09%-15.64M

285.51%88.78M

-170.61%-32.87M

Net income continuous Operations

-160.93%-19.91M

104.53%5.7M

1.93%-15.34M

116.08%8.2M

24.21%-19.86M

199.33%32.68M

33.85%-125.77M

54.96%-15.64M

-24.43%-51.04M

-156.27%-26.2M

Net income discontinuous operations

----

--0

64.79%125.91M

--0

2,144.32%139.81M

---6.67M

Minority interest income

Net income attributable to the parent company

-160.93%-19.91M

4,088.24%5.7M

1.93%-15.34M

-90.76%8.2M

39.60%-19.86M

181.43%32.68M

100.12%136K

62.09%-15.64M

285.51%88.78M

-170.61%-32.87M

Preferred stock dividends

Other preferred stock dividends

Net income attributable to common stockholders

-160.93%-19.91M

4,088.24%5.7M

1.93%-15.34M

-90.76%8.2M

39.60%-19.86M

181.43%32.68M

100.12%136K

62.09%-15.64M

285.51%88.78M

-170.61%-32.87M

Basic earnings per share

-155.32%-2.08

0.64

15.71%-1.77

-91.92%0.94

47.70%-2.27

168.49%3.76

67.03%-2.1

257.16%11.63

-160.28%-4.34

Diluted earnings per share

-155.47%-2.08

0.64

15.71%-1.77

-91.92%0.94

47.70%-2.27

168.31%3.75

67.03%-2.1

257.16%11.63

-160.28%-4.34

Dividend per share

Currency Unit

USD

Accounting Standards

US-GAAP

Audit Opinions

Unqualified Opinion with Explanatory Notes

	(Q1)Mar 31, 2026	(FY)Dec 31, 2025	(Q4)Dec 31, 2025	(Q3)Sep 30, 2025	(Q2)Jun 30, 2025	(Q1)Mar 31, 2025	(FY)Dec 31, 2024	(Q4)Dec 31, 2024	(Q3)Sep 30, 2024	(Q2)Jun 30, 2024
Total revenue	358K	789K	789K	0	0	0	0	0	0	0
Operating revenue	--358K	--789K	--789K	--0	--0	--0	--0	--0	--0	--0
Cost of revenue	0	85.28%6.54M	-83.24%592K	736K	1.69M	3.53M	3.53M	3.53M	0	0
Gross profit	110.15%358K	-62.94%-5.76M	105.58%197K	-736K	-1.69M	-3.53M	-3.53M	-3.53M	0	0
Operating expense	-10.31%21.27M	-25.10%88.22M	-22.64%19.57M	-25.47%21.74M	-19.67%23.19M	-31.15%23.71M	-39.63%117.78M	-31.66%25.3M	-34.58%29.17M	-62.48%28.87M
Selling and administrative expenses	-32.12%8.07M	-26.37%39.16M	-39.50%7.54M	-25.44%9.48M	-21.52%10.25M	-20.45%11.89M	-31.38%53.18M	-10.86%12.46M	-34.59%12.71M	-53.42%13.07M
-General and administrative expense	-32.12%8.07M	-26.37%39.16M	-39.50%7.54M	-25.44%9.48M	-21.52%10.25M	-20.45%11.89M	-31.38%53.18M	-10.86%12.46M	-34.59%12.71M	-53.42%13.07M
Research and development costs	11.62%13.2M	-24.06%49.06M	-9.01%11.68M	-23.35%12.62M	-18.14%12.94M	-39.36%11.82M	-45.07%64.6M	-44.27%12.84M	-34.56%16.46M	-66.22%15.81M
Other operating expenses	----	----	----	---351K	----	----	----	----	----	-222.93%-2.59M
Operating profit	23.24%-20.91M	22.54%-93.97M	32.80%-19.38M	22.94%-22.48M	13.82%-24.88M	20.91%-27.24M	37.82%-121.32M	22.12%-28.84M	34.58%-29.17M	-158.30%-28.87M
Net non-operating interest income expense	-47.41%325K	-43.86%2.23M	1.83%445K	-5.21%618K	-55.61%546K	-40.00%618K	-17.92%3.97M	-77.83%437K	-74.65%652K	184.19%1.23M
Non-operating interest income	-47.41%325K	-43.86%2.23M	1.83%445K	-5.21%618K	-55.61%546K	-62.50%618K	-45.66%3.97M	-77.83%437K	-74.65%652K	-28.74%1.23M
Non-operating interest expense	----	--0	----	----	--0	--0	--0	--0	--0	--0
Other net income (expense)	-98.87%669K	1,256.83%97.44M	-71.81%3.6M	233.51%30.06M	210.03%4.48M	11,642.57%59.3M	-6,385.82%-8.42M	3,697.92%12.76M	-2,353.95%-22.52M	195.63%1.45M
Special income (charges)	--0	1,319.51%80.69M	-80.70%1.1M	--27.22M	--185K	--52.18M	--5.68M	--5.68M	--0	--0
-Gain on sale of business	--0	1,319.51%80.69M	-80.70%1.1M	--27.22M	--185K	--52.18M	--5.68M	--5.68M	--0	--0
Other non- operating income (expenses)	-90.60%669K	218.77%16.76M	-64.67%2.5M	112.62%2.84M	197.23%4.3M	1,309.70%7.12M	-10,627.61%-14.11M	2,006.25%7.08M	-2,353.95%-22.52M	195.63%1.45M
Income before tax	-160.93%-19.91M	104.53%5.7M	1.93%-15.34M	116.08%8.2M	24.21%-19.86M	199.33%32.68M	33.85%-125.77M	54.96%-15.64M	-24.43%-51.04M	-156.27%-26.2M
Income tax
Net income	-160.93%-19.91M	4,088.24%5.7M	1.93%-15.34M	-90.76%8.2M	39.60%-19.86M	181.43%32.68M	100.12%136K	62.09%-15.64M	285.51%88.78M	-170.61%-32.87M
Net income continuous Operations	-160.93%-19.91M	104.53%5.7M	1.93%-15.34M	116.08%8.2M	24.21%-19.86M	199.33%32.68M	33.85%-125.77M	54.96%-15.64M	-24.43%-51.04M	-156.27%-26.2M
Net income discontinuous operations	----	--0	--0	--0	--0	--0	64.79%125.91M	--0	2,144.32%139.81M	---6.67M
Minority interest income
Net income attributable to the parent company	-160.93%-19.91M	4,088.24%5.7M	1.93%-15.34M	-90.76%8.2M	39.60%-19.86M	181.43%32.68M	100.12%136K	62.09%-15.64M	285.51%88.78M	-170.61%-32.87M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders	-160.93%-19.91M	4,088.24%5.7M	1.93%-15.34M	-90.76%8.2M	39.60%-19.86M	181.43%32.68M	100.12%136K	62.09%-15.64M	285.51%88.78M	-170.61%-32.87M
Basic earnings per share	-155.32%-2.08	0.64	15.71%-1.77	-91.92%0.94	47.70%-2.27	168.49%3.76	0	67.03%-2.1	257.16%11.63	-160.28%-4.34
Diluted earnings per share	-155.47%-2.08	0.64	15.71%-1.77	-91.92%0.94	47.70%-2.27	168.31%3.75	0	67.03%-2.1	257.16%11.63	-160.28%-4.34
Dividend per share
Currency Unit	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Accounting Standards	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP
Audit Opinions	--	Unqualified Opinion with Explanatory Notes	--	--	--	--	Unqualified Opinion with Explanatory Notes	--	--	--

No. Symbol 5D % Chg

Middle East conflict spreads to the stock market! How should investors respond?

On May 7 Eastern Time, as the US-Iran negotiations entered a critical window amid external expectations and various parties' strategic maneu Show More

牛牛課堂

Mar 4 17:09

Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.

牛牛課堂

Mar 18 18:18

Hormuz, Term Structure and USO: Navigating the Energy Storm